Lexicon Pharmaceuticals (id:8009 LXRX)
0.860 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:53:23 PM)
Exchange closed, opens in 20 hours 36 minutes
About Lexicon Pharmaceuticals
Market Capitalization 327.15M
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Headquarters (address) |
2445 Technology Forest Boulevard The Woodlands 77381 TX United States |
| Phone | 281 863 3000 |
| Website | https://www.lexpharma.com |
| Employees | 285 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LXRX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.730 - 3.73 |
| Market Capitalization | 327.15M |
| P/E trailing | -1.09 |
| P/E forward | -1.51 |
| Price/Sale | 62.56 |
| Price/Book | 1.83 |
| Beta | 1.24 |
| EPS | -0.740 |
| EPS United States (ID:6, base:3402) | 24.22 |